{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T05:26:44Z","timestamp":1764912404025,"version":"3.46.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prophylactic immunosuppressants for graft-versus-host disease (GVHD) in allogeneic hematopoietic cell transplantation (alloHCT), including post-transplant cyclophosphamide (PTCy) and mycophenolate mofetil (MMF), exhibit complex pharmacokinetic profiles. Interindividual variations in pharmacokinetic exposure to these immunosuppressants or their metabolites may interfere with treatment outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>\n                      A feasibility study (n = 11) was conducted to investigate the pharmacokinetic\/pharmacodynamic relationship in patients undergoing HLA-haploidentical alloHCT with standard high-dose PTCy (50 mg\u00b7kg\n                      <jats:sup>\u22121<\/jats:sup>\n                      \u00b7day\n                      <jats:sup>\u22121<\/jats:sup>\n                      on days +3\/+4) combined with MMF and tacrolimus or sirolimus. Blood samples were collected to assess the variability in pharmacokinetic biomarkers, including exposures [areas under the curve (AUCs)] to cyclophosphamide (Cy), carboxycyclophosphamide (cepm),\n                      <jats:italic>N<\/jats:italic>\n                      -dechloroethyl cyclophosphamide (dccy), 4-ketocyclophosphamide (ketocy), mycophenolic acid (MPA), and mycophenolic acid glucuronide (MPAG). Serial dynamic changes in immune cell populations, including regulatory T cells (Tregs), over the first 3 post-transplant weeks were monitored.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A transient reduction in the proliferation (Ki-67\n                      <jats:sup>+<\/jats:sup>\n                      ) of activated (HLA-DR\n                      <jats:sup>+<\/jats:sup>\n                      ) T cells coincided with Cy treatment. The ratio of Tregs to the CD4\n                      <jats:sup>+<\/jats:sup>\n                      T-cell population increased in a time-dependent manner within the first 21 days post-transplant. We observed moderate interindividual variability across all pharmacokinetic biomarkers. Serum creatinine and blood urea nitrogen levels positively correlated with exposure to Cy and MMF metabolites, including cepm, MPA, and MPAG. Using correlation analysis, we further confirmed the negative association between pharmacokinetic (PK) biomarkers and lymphocyte count, but not Treg percentage, suggesting that careful optimization of Cy and MMF dosing may have the potential to support immune recovery, although this requires further validation in larger studies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The relationship of pharmacokinetic biomarkers to immune and clinical outcomes warrants further investigation in larger studies but holds promise for personalizing dosing of GVHD prophylaxis to improve patient outcomes after alloHCT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1694754","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T05:13:31Z","timestamp":1764911611000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of pharmacokinetic biomarkers with early immune recovery following HLA-haploidentical hematopoietic cell transplantation"],"prefix":"10.3389","volume":"16","author":[{"given":"Guofang","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy W.","family":"Synold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanzay","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Horne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher G.","family":"Kanakry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryotaro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2021.02.011","article-title":"Early cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantation","volume":"3","author":"Dulery","year":"2021","journal-title":"JACC Cardio Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014879","article-title":"Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation","volume":"9","author":"Hyder","year":"2025","journal-title":"Blood Adv"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02293","article-title":"Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic Malignancies","volume":"40","author":"Luznik","year":"2022","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009362","article-title":"Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis","volume":"137","author":"Goldsmith","year":"2021","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17563","article-title":"Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation","volume":"194","author":"Mulroney","year":"2021","journal-title":"Br J Haematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.09.015","article-title":"Post-transplantation cyclophosphamide is associated with an increase in non-cytomegalovirus herpesvirus infections in patients with acute leukemia and myelodysplastic syndrome","volume":"28","author":"Singh","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B7","doi-asserted-by":"publisher","first-page":"114 e111","DOI":"10.1016\/j.jtct.2023.09.017","article-title":"Incidence and impact of fungal infections in post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical hematopoietic cell transplantation: A center for international blood and marrow transplant research analysis","volume":"30","author":"Papanicolaou","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41409-023-02131-z","article-title":"Post-transplantation cyclophosphamide is associated with increased bacterial infections","volume":"59","author":"Ustun","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"B9","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/s41409-020-01065-0","article-title":"Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation","volume":"56","author":"Sugita","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01908-y","article-title":"Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological Malignancies","volume":"58","author":"Dulery","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2024.2313357","article-title":"More about post-transplant cyclophosphamide in haploidentical grafts: full or reduced doses","volume":"29","author":"Gallardo-Perez","year":"2024","journal-title":"Hematology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544110-00003","article-title":"Clinical pharmacokinetics of cyclophosphamide","volume":"44","author":"de Jonge","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2232-8","article-title":"A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients","volume":"72","author":"Bemer","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2015.1.215","article-title":"Immune reconstitution following stem cell transplantation","volume":"2015","author":"van den Brink","year":"2015","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00507","article-title":"Immune reconstitution after allogeneic hematopoietic stem cell transplantation","volume":"7","author":"Ogonek","year":"2016","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"211ra157","DOI":"10.1126\/scitranslmed.3006960","article-title":"Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide","volume":"5","author":"Kanakry","year":"2013","journal-title":"Sci Transl Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-525873","article-title":"Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice","volume":"124","author":"Ganguly","year":"2014","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.04.025","article-title":"Post-transplantation cyclophosphamide and sirolimus after haploidentical hematopoietic stem cell transplantation using a treosulfan-based myeloablative conditioning and peripheral blood stem cells","volume":"21","author":"Cieri","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1172\/JCI124218","article-title":"Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression","volume":"129","author":"Wachsmuth","year":"2019","journal-title":"J Clin Invest"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.09.030","article-title":"Optimized timing of post-transplantation cyclophosphamide in MHC-haploidentical murine hematopoietic cell transplantation","volume":"26","author":"Wachsmuth","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.796349","article-title":"Post-transplantation cyclophosphamide uniquely restrains alloreactive CD4(+) T-cell proliferation and differentiation after murine MHC-haploidentical hematopoietic cell transplantation","volume":"13","author":"Hadjis","year":"2022","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e162180","DOI":"10.1172\/jci.insight.162180","article-title":"Hematopoietic stem cell-derived Tregs are essential for maintaining favorable B cell lymphopoiesis following posttransplant cyclophosphamide","volume":"8","author":"Sumii","year":"2023","journal-title":"JCI Insight"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/41.7.1011","article-title":"Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics","volume":"41","author":"Nowak","year":"1995","journal-title":"Clin Chem"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1064","article-title":"Mycophenolic acid and its metabolites in kidney transplant recipients: A semimechanistic enterohepatic circulation model to improve estimating exposure","volume":"58","author":"Okour","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1860","article-title":"Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation","volume":"101","author":"McDonald","year":"2003","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-608406","article-title":"Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation","volume":"125","author":"Roberto","year":"2015","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4994","DOI":"10.1182\/bloodadvances.2022006961","article-title":"Efflux capacity and aldehyde dehydrogenase both contribute to CD8+ T-cell resistance to posttransplant cyclophosphamide","volume":"6","author":"Patterson","year":"2022","journal-title":"Blood Adv"},{"key":"B28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40364-025-00749-3","article-title":"Pharmacokinetics of post-transplant cyclophosphamide and its associations with clinical outcomes in pediatric haploidentical hematopoietic stem cell transplantation","volume":"13","author":"Hong","year":"2025","journal-title":"biomark Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.5581\/1516-8484.20120108","article-title":"Early lymphocyte recovery as a predictor of outcome, including relapse, after hematopoietic stem cell transplantation","volume":"34","author":"Morando","year":"2012","journal-title":"Rev Bras Hematol Hemoter"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.01.019","article-title":"Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome","volume":"21","author":"Kim","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B31","first-page":"5779","article-title":"Immune reconstitution impact on overall survival after hematopoietic haploidentical stem cell transplantation","volume-title":"Blood","author":"Perez-Corral","year":"2016"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2023.05.012","article-title":"Early immune reconstitution as predictor for outcomes after allogeneic hematopoietic cell transplant; a tri-institutional analysis","volume":"25","author":"Troullioud Lucas","year":"2023","journal-title":"Cytotherapy"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.03.032","article-title":"Pharmacokinetic and pharmacodynamic analysis of inosine monophosphate dehydrogenase activity in hematopoietic cell transplantation recipients treated with mycophenolate mofetil","volume":"20","author":"Li","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.59","article-title":"Delayed neutrophil engraftment in cord blood transplantation with intensive administration of mycophenolate mofetil for GVHD prophylaxis","volume":"46","author":"Okamura","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"B35","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13568-020-01064-w","article-title":"Synthesis of cyclophosphamide metabolites by a peroxygenase from Marasmius rotula for toxicological studies on human cancer cells","volume":"10","author":"Steinbrecht","year":"2020","journal-title":"AMB Express"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199706000-00018","article-title":"Effect of mycophenolic acid glucuronide on inosine monophosphate dehydrogenase activity","volume":"19","author":"Nowak","year":"1997","journal-title":"Ther Drug Monit"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13239","article-title":"Pharmacometabonomic association of cyclophosphamide 4-hydroxylation in hematopoietic cell transplant recipients","volume":"15","author":"McCune","year":"2022","journal-title":"Clin Transl Sci"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13404","article-title":"Lipidomics of cyclophosphamide 4-hydroxylation in patients receiving post-transplant cyclophosphamide","volume":"15","author":"Navarro","year":"2022","journal-title":"Clin Transl Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfl844","article-title":"Use of mycophenolic acid in non-transplant renal diseases","volume":"22","author":"Stassen","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"B40","doi-asserted-by":"publisher","first-page":"10.1681\/ASN.2024s5j6gaha","DOI":"10.1681\/ASN.2024s5j6gaha","article-title":"Post-transplantation cyclophosphamide-based regimen for graft-vs.-host disease prophylaxis reduces risk of CKD in allogenic stem-cell transplant recipients: FR-OR79","volume":"35","author":"Klair","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2002.00279.x","article-title":"Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency","volume":"61","author":"Haubitz","year":"2002","journal-title":"Kidney Int"},{"key":"B42","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/pbc.20558","article-title":"Cyclophosphamide disposition in an anephric child","volume":"46","author":"McCune","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2144","article-title":"Influence of renal function on phosphoramide mustard exposure: A nonlinear mixed-effects analysis","volume":"63","author":"Jaber","year":"2023","journal-title":"J Clin Pharmacol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000276936.14041.6c","article-title":"The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide","volume":"84","author":"Naesens","year":"2007","journal-title":"Transplantation"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1694754\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T05:13:31Z","timestamp":1764911611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1694754\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":44,"alternative-id":["10.3389\/fimmu.2025.1694754"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1694754","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"article-number":"1694754"}}